False Claims Act Insights - Bitter Pills: DOJ Targets Pharmacies for FCA Enforcement
Prescribing GLP-1 Medications: Be Aware of Legal Limitations
Understanding Pharmacy Benefit Managers: The PBM Landscape Explained
The DEA Is Knocking at Your Door . . . Are You Prepared? – Diagnosing Health Care
340B Drug Pricing Program Compliance
Podcast: Post-Dobbs Access to Reproductive Health Care and Abortion-Inducing Drugs - Diagnosing Health Care
Podcast: Impact of COVID-19 on Pharmacist Scope of Practice: Before and After the PREP Act - Diagnosing Health Care
Hooper, Kearney and Macklin on Cutting Edge Topics in the False Claims Act
Edible Bites Episode 3: Cannabis and Life Sciences Video Webinar Series
Health Care Continues to Drive False Claims Act Recoveries: Thought Leaders in Health Law Video Series
Drug Pricing Initiatives During the Trump Presidency
Bill on Bankruptcy: AMR Make-Whole Opinion Vulnerable on Appeal
Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick...more
WindRose Health Investors has announced a strategic investment in Stellus Rx. Stellus Rx, founded in 2022 and based in Plano, Texas, provides pharmacist-led patient support and dispensing solutions....more
CVS to Pay $37.8 Million to Settle Overbilling Claims - CVS Pharmacy, Inc. agreed to pay $37.8 million to settle several lawsuits in which the United States intervened that alleged that CVS over-dispensed and overbilled...more
Changes to the Insurance Act will create an “Any Willing Provider” framework that will require group insurance providers to allow any pharmacy to dispense drugs that it reimburses on the same terms as it offers to other...more
Le 6 novembre 2025, le gouvernement provincial de l’Ontario a publié son Exposé de l’automne 2025 (l’« Exposé de l’automne »), qui propose de réglementer les réseaux de fournisseurs privilégiés (les « RFP ») dans le cadre de...more
The rapid rise of GLP-1 weight loss drugs such as semaglutide and tirzepatide has created two parallel markets. One market consists of FDA-approved products used under typical prescribing conditions. The other is a patchwork...more
Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs). As we previously reported, there has...more
On November 6, 2025, the Ontario provincial government released its 2025 Fall Statement (Fall Statement), which proposes to regulate preferred provider networks (PPNs) in employer-sponsored drug plans. Current PPN...more
Sheridan Capital Partners has sold Tarrytown Expocare Pharmacy to Carlyle, according to a news release. ...more
On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used therapies. These include...more
Background- The case involved an owner and operator of pharmacies charged with healthcare fraud and kickback charges based on alleged participation in a drug diversion scheme. Before deliberations began, the district court...more
An artificial intelligence (AI) triage model piloted in the emergency department can become a deterioration predictor on med-surg floors and then prioritized on a radiology worklist. A lab‑developed sepsis panel built in the...more
The pharmaceutical retailer AvKARE has published a voluntary recall notice for five different types of eye drops previously available through the company’s online store. The recall involves products sold by BRS Analytical...more
On October 28, 2025, the Rhode Island Department of Health (“RIDOH”) issued a public notice of a proposed amendment to 216-RICR-40-15-1: “Pharmacists, Pharmacies, and Manufacturers, Wholesalers, and Distributors” (the...more
This week the FDA granted interchangeability status to Fresenius Kabi’s and Celltrion’s respective denosumab biosimilars. Interchangeable biosimilars can be substituted for the reference product at the pharmacy without...more
Executive Summary - Effective January 1, 2026, California’s Senate Bill 41 (SB 41) fundamentally reforms pharmacy benefit manager (PBM) practices. It prohibits spread pricing, mandates a passthrough pricing model, and...more
On October 21, 2025, the Patented Medicine Prices Review Board (PMPRB) announced the release of CompassRx (10th edition), an annual report that analyzes factors driving prescription drug expenditures in Canadian public drug...more
At its October 2025 board meeting, the Alabama Board of Pharmacy (the “Board”) voted to remove a requirement that new wholesale distributor applicants sign an affidavit affirming that products distributed in Alabama will only...more
The California State Board of Pharmacy (the “Board”) has proposed amendments to its rule regulating central fill pharmacies, Cal. Code Reg. tit. 16, § 1707.4, through a recent Notice of Proposed Action. The comment period is...more
As pharmaceutical manufacturers, digital health companies and telehealth platforms continue to reshape the delivery of medications, DTC pharmacy models have emerged as a critical component of patient engagement and...more